Product
IFX-1 + Pembrolizumab Combination Therapy
1 clinical trial
1 indication
Indication
Squamous Cell Carcinoma of SkinClinical trial
Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)Status: Active (not recruiting), Estimated PCD: 2024-06-30